CHICAGO – Antipsychotic medication was associated with a modest and time-limited increased risk of myocardial infarction (heart attack) among older patients treated with cholinesterase inhibitors for dementia, according to a study published Online First by Archives of Internal Medicine, one of the JAMA/Archives journals.
Antipsychotic medications are commonly prescribed for older patients to manage the symptoms of dementia, which can include physical aggression, agitation and hallucinations. For this indication, previous studies have suggested the use of antipsychotic agents (APs) was linked to an increased risk of stroke and safety warnings were issued in several countries. Studies focusing on the risk of death from all causes led to similar conclusions. However, the effect of AP use on the risk of acute myocardial infarction (MI) in patients with treated dementia "remains poorly examined," the authors write in their study background. .
Antoine Pariente, M.D., Ph.D., then of the Université de Montreal, Canada, now of Université Bordeaux Ségalen, France, and colleagues investigated the risk of MI associated with the use of APs in patients with dementia treated with cholinesterase inhibitors (ChIs). Using the Quebec, Canada, prescription claims database, the authors identified 37,138 patients during the study period (January 2000 through December 2009) who were 66 years or older and had ChI treatment. Of them, 10,969 (29.5 percent) started AP treatment during the study period. They were matched with 10,969 non-AP users.
"Our study results indicate that the use of APs is associated with a modest increase in the risk of MI among community-dwelling older patients with treated dementia," the authors note. "The increased risk seems to be highest at the beginning of treatment and seems to decrease thereafter, with the first month of treatment accounting for the highest period of risk."
The results indicate that within one year of starting AP treatment, 1.3 percent of the patients had an incident MI. Hazard ratios for the risk of MI after initiating AP treatment were 2.19 for the first 30 days; 1.62 for the first 60 days; 1.36 for the first 90 days and 1.15 for the first 365 days.
Researchers also performed a self-controlled case series (SCCS) study among 804 new AP users who had an incident MI. The results indicate incidence rate ratios of 1.78 for the one- to 30-day period; 1.67 for the 31- to 60-day period; 1.37 for the 61-to 90-day period; 1.18 for the remaining exposure period; and 0.80 for the withdrawal period.
"Because AP use is frequent in patients with dementia (29.5 percent in our study population), the increased risk of MI may have a major public health effect, which highlights the need for communicating such risk and for close monitoring of patients during the first weeks of treatment," the authors conclude.
(Arch Intern Med. Published online March 26, 2012. doi:10.1001/archinternmend.2012.28. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: The study was funded by the Fonds de la Recherche en Santé du Québec and by the Réseau Québécois de Recherche sur l'Usage des Médicaments. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Invited Commentary: Questions Raised About How Drug Exposure Leads to Death
In an invited commentary, Sudeep S. Gill, M.D., M.Sc., and Dallas P. Seitz, M.D., of Queen's University, Kingston, Ontario, Canada, write: "The increased risk for death associated with antipsychotic use has raised several important questions, and among them is the question of how exposure to these drugs leads to death."
"Important lessons about the pathogenesis of cardiovascular disease may underlie the observed association between antipsychotic drug use and AMI (acute myocardial infarction) that is described by Pariente et al, but we must await further research to clarify the mechanisms contributing to this association," they comment.
"Meanwhile, physicians should limit prescribing of antipsychotic drugs to patients with dementia and instead use other techniques when available, such as environmental and behavioral strategies, to keep these patients safe and engaged."
(Arch Intern Med. Published online March 26, 2012. doi:10.1001/archinternmed.2012.682. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: The invited commentary authors disclosed financial support and one is a paid member of an independent advisory group on drug-related issues for the Ontario Ministry of Health and Long-term Care. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
For More Information: Contact JAMA/Archives Media Relations at 312-464-JAMA or email: mediarelations@jama-archives.org.
Media Advisory: To contact corresponding author Yola Moride, Ph.D., call William Raillant-Clark at 514-343-7593 or email w.raillant-clark@umontreal.ca. To contact corresponding commentary author Sudeep S. Gill, M.D., M.Sc., call Anne Craig at 613-533-2877 or email anne.craig@queensu.ca.
Journal
Archives of Internal Medicine